JP7631218B2 - (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 - Google Patents
(6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 Download PDFInfo
- Publication number
- JP7631218B2 JP7631218B2 JP2021559890A JP2021559890A JP7631218B2 JP 7631218 B2 JP7631218 B2 JP 7631218B2 JP 2021559890 A JP2021559890 A JP 2021559890A JP 2021559890 A JP2021559890 A JP 2021559890A JP 7631218 B2 JP7631218 B2 JP 7631218B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- added
- acid
- give
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025017468A JP7885383B2 (ja) | 2019-04-11 | 2025-02-05 | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832614P | 2019-04-11 | 2019-04-11 | |
| US62/832,614 | 2019-04-11 | ||
| PCT/US2020/027655 WO2020210613A1 (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025017468A Division JP7885383B2 (ja) | 2019-04-11 | 2025-02-05 | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526659A JP2022526659A (ja) | 2022-05-25 |
| JP2022526659A5 JP2022526659A5 (cg-RX-API-DMAC7.html) | 2023-04-12 |
| JP7631218B2 true JP7631218B2 (ja) | 2025-02-18 |
Family
ID=70457148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559890A Active JP7631218B2 (ja) | 2019-04-11 | 2020-04-10 | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 |
| JP2025017468A Active JP7885383B2 (ja) | 2019-04-11 | 2025-02-05 | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025017468A Active JP7885383B2 (ja) | 2019-04-11 | 2025-02-05 | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023545129A (ja) * | 2020-10-12 | 2023-10-26 | ブリストル-マイヤーズ スクイブ カンパニー | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}- 1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016053455A1 (en) | 2014-10-01 | 2016-04-07 | Bristol-Myers Squibb Company | Pyrimidinones as factor xia inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013033777A2 (pt) * | 2011-03-15 | 2016-09-13 | Abbvie Inc | moduladores de receptor de hormônio nuclear |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CN105294496A (zh) | 2015-09-28 | 2016-02-03 | 中山大学 | 一种西酞普兰中间体的制备方法 |
| CN110062757B (zh) | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| CN113677682B (zh) | 2019-04-16 | 2023-05-30 | 华润生物医药有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CA3179679A1 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Carboxyesterase polypeptides for kinetic resolution |
-
2020
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-10 CN CN202080041935.8A patent/CN114375290B/zh active Active
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 ES ES20721374T patent/ES2969253T3/es active Active
- 2020-04-10 JP JP2021559890A patent/JP7631218B2/ja active Active
- 2020-04-10 EA EA202192807A patent/EA202192807A1/ru unknown
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/pt unknown
- 2020-04-10 IL IL287102A patent/IL287102B2/en unknown
- 2020-04-10 MX MX2025014306A patent/MX2025014306A/es unknown
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/es unknown
- 2020-04-10 TW TW109112263A patent/TWI880924B/zh active
- 2020-04-10 KR KR1020267004972A patent/KR20260047658A/ko active Pending
- 2020-04-10 AU AU2020272973A patent/AU2020272973B2/en active Active
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en not_active Ceased
- 2020-04-10 KR KR1020217036807A patent/KR102929951B1/ko active Active
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 CN CN202411615118.5A patent/CN119775276A/zh active Pending
- 2020-04-10 US US17/602,059 patent/US12378246B2/en active Active
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-13 AR ARP200101024A patent/AR118649A1/es unknown
-
2025
- 2025-02-05 JP JP2025017468A patent/JP7885383B2/ja active Active
- 2025-06-18 US US19/242,506 patent/US20260092066A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201396A patent/AU2026201396A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016053455A1 (en) | 2014-10-01 | 2016-04-07 | Bristol-Myers Squibb Company | Pyrimidinones as factor xia inhibitors |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023545129A (ja) * | 2020-10-12 | 2023-10-26 | ブリストル-マイヤーズ スクイブ カンパニー | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}- 1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造方法 |
| JP7844457B2 (ja) | 2020-10-12 | 2026-04-13 | ブリストル-マイヤーズ スクイブ カンパニー | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}- 1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025084766A (ja) | (6r,10s)-10-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1(6h)-ピリミジニル}-1-(ジフルオロメチル)-6-メチル-1,4,7,8,9,10-ヘキサヒドロ-11,15-(メタノ)ピラゾロ[4,3-b][1,7]ジアザシクロテトラデシン-5(6h)-オンの製造における新規合成法 | |
| EP2968299B1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| Kozikowski et al. | Synthesis of huperzine A, its analogs, and their anticholinesterase activity | |
| KR101395377B1 (ko) | Hiv 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물 | |
| ZA200601055B (en) | Regioselective synthesis of CCI-779 | |
| KR101379154B1 (ko) | 카르보닐 비대칭 알킬화 | |
| KR100926844B1 (ko) | 스핑고신의 합성을 위한 제조방법 | |
| CN114539304B (zh) | 一类1,3-氮杂硅烷化合物的合成方法及其应用 | |
| HK40124045A (en) | Novel synthetic options towards the manufacture of a compound | |
| WO2002022618A1 (fr) | Preparation de la camptothecine et de ses derives | |
| EA050867B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ (6R,10S)-10-{4-[5-ХЛОРО-2-(4-ХЛОРО-1Н-1,2,3-ТРИАЗОЛ-1-ИЛ)ФЕНИЛ]-6-ОКСО-1(6Н)-ПИРИМИДИНИЛ}-1-(ДИФТОРОМЕТИЛ)-6-МЕТИЛ-1,4,7,8,9,10-ГЕКСАГИДРО-11,15-(МЕТЕНО)ПИРАЗОЛО[4,3-b][1,7]ДИАЗАЦИКЛОТЕТРАДЕЦИН-5(6Н)-ОНА | |
| JP6235473B2 (ja) | 大環状hcvプロテアーゼ阻害剤を製造するための方法および中間体 | |
| JP4524845B2 (ja) | アミノ基を有する光学活性アリルアルコール誘導体の製造方法、および光学活性化合物 | |
| EP1452520A1 (en) | A process for the synthesis of sphingosine | |
| KR100576740B1 (ko) | 스핑고신 전구체 화합물, 그 제조방법 및 이를 이용한 스핑고신 | |
| CN119060047A (zh) | 氟代多羟基吲哚里西啶类化合物及其药学上可接受的盐及合成方法和糖苷酶抑制剂及应用 | |
| JP2001348383A (ja) | ジヒドロキノリン誘導体およびジヒドロイソキノリン誘導体の立体選択的製造法 | |
| JP2000026455A (ja) | 3−アミノチオフェン誘導体 | |
| CN105315159A (zh) | 一种化合物的拆分方法 | |
| JP2003183277A (ja) | エピヒマンドラビン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230404 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241021 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250205 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7631218 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |